{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:15:12Z","timestamp":1777630512230,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":4912,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1111\/j.1538-7836.2009.03381.x","type":"journal-article","created":{"date-parts":[[2009,7,13]],"date-time":"2009-07-13T07:24:21Z","timestamp":1247469861000},"page":"71-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"S1","title":["Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance"],"prefix":"10.1016","volume":"7","author":[{"given":"G.","family":"CASTAMAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"TOSETTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"RODEGHIERO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0010","first-page":"94","article-title":"Von Willebrand\u2019s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.cb.06.110190.001245","article-title":"Cell biology of von Willebrand factor","volume":"6","author":"Wagner","year":"1990","journal-title":"Annu Rev Cell Biol"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V94.1.179.413k18_179_185","article-title":"von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation","volume":"94","author":"Van Mourik","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0025","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"Haberichter","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0030","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0035","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1538-7836.2007.02572.x","article-title":"Clearance mechanisms of von Willebrand factor and factor VIII","volume":"5","author":"Lenting","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0040","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"Gallinaro","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1538-7836.2003.00007.x","article-title":"An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13","volume":"1","author":"Bowen","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood-2003-05-1505","article-title":"An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13","volume":"103","author":"Bowen","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0055","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1074\/jbc.M310436200","article-title":"An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation","volume":"279","author":"Lenting","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0060","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood.V88.5.1692.1692","article-title":"Clearance of normal and type 2 A von Willebrand factor in the rat","volume":"88","author":"Stoddart","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0065","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/j.1538-7836.2005.01571.x","article-title":"Cysteine-mutations in von Willebrand factor associated with increased clearance","volume":"3","author":"Van Schooten","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0070","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2008-01-133181","article-title":"Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo","volume":"112","author":"Van Schooten","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0075","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7326\/0003-4819-103-1-6","article-title":"Response of patients with mild and moderate hemophilia A and von Willebrand\u2019s disease to treatment with desmopressin","volume":"103","author":"De La Fuente","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V99.1.180","article-title":"Reduced von Willebrand factor survival in type Vicenza von Willebrand disease","volume":"99","author":"Casonato","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0090","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0037-1614019","article-title":"An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation","volume":"84","author":"Castaman","year":"2000","journal-title":"Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0095","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"Haberichter","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0100","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1160\/TH07-09-0565","article-title":"Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations","volume":"99","author":"Millar","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0105","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1538-7836.2008.02945.x","article-title":"Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)","volume":"6","author":"Budde","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2009.03381.x_bb0110","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3385.3385","article-title":"A prospective evaluation of bleeding tendency and efficacy of antihemorrhagic treatments in patients with increased von Willebrand factor (VWF) clearance (von Willebrand disease Vicenza and C1130F mutation","volume":"112","author":"Castaman","year":"2008","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2009.03381.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622174015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622174015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2009.03381.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:47:16Z","timestamp":1761533236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622174015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":21,"alternative-id":["S1538783622174015"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03381.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03381.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}